About the Company
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.
Employees
15
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $OCGN News
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
Ocugen is gearing up to report results from the two phase 1/2 studies for the treatment of patients with GA and Stargardt ...
Ocugen (OCGN) Price Target Decreased by 15.79% to 5.44
The average one-year price target for Ocugen (NasdaqCM:OCGN) has been revised to 5.44 / share. This is an decrease of 15.79% ...
Ocugen, Inc. (OCGN)
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...
Ocugen's OCU410ST Advances in Clinical Trial for Stargardt Disease, Moving to Medium Dose Testing
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced a significant advancement in its ongoing clinical trial for ...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds ...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed ...
P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf ...
Ocugen Inc announces FDA clearance of IND amendment to Initiate OCU400 Phase 3 clinical trial
The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the ...
Ocugen stock price is flying: beware of this crucial OCGN risk
Ocugen (NASDAQ: OCGN) stock price has been one of the best-performing companies in Wall Street this year. It has jumped by ...
Ocugen's IND Amendment To Commence OCU400 Phase 3 Trial Gets FDA Approval
(RTTNews) - Monday, Ocugen, Inc.(OCGN) revealed that the FDA has approved the Company's Investigational New Drug or IND amendment to commence a Phase 3 clinical trial of OCU400. OCU400 is a gene ...
Ocugen, Inc. (OCGN)
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press ...
Ocugen Inc OCGN
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Loading the latest forecasts...